Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABT
stocks logo

ABT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
11.80B
+7.5%
1.496
+11.64%
11.19B
+8.06%
1.204
+10.47%
11.96B
+7.35%
1.382
+9.66%
Estimates Revision
The market is revising Downward the revenue expectations for Abbott Laboratories (ABT) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -5.67%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.24%
In Past 3 Month
Stock Price
Go Down
down Image
-5.67%
In Past 3 Month
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 147.13 USD with a low forecast of 136.00 USD and a high forecast of 162.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 147.13 USD with a low forecast of 136.00 USD and a high forecast of 162.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 125.400
sliders
Low
136.00
Averages
147.13
High
162.00
Current: 125.400
sliders
Low
136.00
Averages
147.13
High
162.00
Jefferies
Jefferies
Buy
to
Hold
downgrade
$90 -> $105
2025-11-24
Reason
Jefferies
Jefferies
Price Target
$90 -> $105
2025-11-24
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $90, citing the pending acquisition by Abbott (ABT). The firm thinks the takeover premium represents a win for Exact Sciences and does not expect another bidder to come over the top given precedent deal multiples.
Barclays
Overweight
maintain
$159 -> $162
2025-10-17
Reason
Barclays
Price Target
$159 -> $162
2025-10-17
maintain
Overweight
Reason
Barclays raised the firm's price target on Abbott to $162 from $159 and keeps an Overweight rating on the shares. The firm recommends using the pullback following the in-line Q3 report as a buying opportunity. The shares were discounting a slightly stronger beat for Q3, the analyst tells investors in a research note. Barclays views the business weakness as temporary, and expects Abbott's portfolio to return to growth toward the high end of its historical ranges in 2026 and beyond.
Wells Fargo
Overweight
maintain
$142 -> $146
2025-10-16
Reason
Wells Fargo
Price Target
$142 -> $146
2025-10-16
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Abbott to $146 from $142 and keeps an Overweight rating on the shares. The firm notes the company reported about in-line Q3 sales and EPS on Nutrition and China Dx headwinds, offset by Medtech and EPD strength. Abbott reiterated 2025 organic sales growth and tightened its EPS guide. The company is comfortable with prior 2026 Street estimates, Wells adds.
Raymond James
Outperform
maintain
$141 -> $146
2025-10-16
Reason
Raymond James
Price Target
$141 -> $146
2025-10-16
maintain
Outperform
Reason
Raymond James raised the firm's price target on Abbott to $146 from $141 and keeps an Outperform rating on the shares. Despite organic revenue growth and EPS that hit consensus, there was an expectation for more, and while Med Devices is accelerating, the rest of the business is experiencing some lumpiness, the analyst tells investors in a research note. The firm continues to see a 7%-8% organic revenue grower capable of growing 10%+ on the bottom-line.
Evercore ISI
Outperform
to
NULL
downgrade
$144 -> $142
2025-10-16
Reason
Evercore ISI
Price Target
$144 -> $142
2025-10-16
downgrade
Outperform
to
NULL
Reason
Evercore ISI lowered the firm's price target on Abbott to $142 from $144 and keeps an Outperform rating on the shares. The Medtech sector shows promising momentum and the underlying performance, especially in Medical Devices, "signals optimism for the future, even as some headline numbers fell slightly short of expectations," the analyst tells investors in a post-earnings note.
Goldman Sachs
initiated
$157
2025-10-01
Reason
Goldman Sachs
Price Target
$157
2025-10-01
initiated
Reason
Goldman Sachs analysts added Abbott to the firm's US Conviction List as part of its monthly update. The company is nearing an inflection in organic revenue growth, driven by a pipeline of new products, the analyst tells investors in a research note. Goldman has a Buy rating on the shares with a $157 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Abbott Laboratories (ABT.N) is 22.54, compared to its 5-year average forward P/E of 24.63. For a more detailed relative valuation and DCF analysis to assess Abbott Laboratories 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
24.63
Current PE
22.54
Overvalued PE
26.84
Undervalued PE
22.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
18.89
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
20.23
Undervalued EV/EBITDA
17.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.83
Current PS
0.00
Overvalued PS
5.26
Undervalued PS
4.41
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ABT News & Events

Events Timeline

(ET)
2025-12-04
13:40:00
FDA Warns to Stop Using Abbott FreeStyle Libre 3 Glucose Monitors
select
link
2025-12-01 (ET)
2025-12-01
03:52:00
Exact Sciences Downgraded to Hold by Stifel After $105 Acquisition Agreement with Abbott
select
2025-11-20 (ET)
2025-11-20
08:09:19
Abbott anticipates that the acquisition of Exact Sciences will quickly enhance organic sales.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
05:00 AMNASDAQ.COM
Key Analyst Insights on HSBC, Abbott, and Shell

  • Research Reports Overview: The Zacks Research Daily highlights new reports on 16 major stocks, including HSBC, Abbott, Shell, and Oak Valley Bancorp, showcasing unique insights into micro-cap stocks and their market performance.

  • HSBC Holdings Performance: HSBC's shares have outperformed the foreign banking industry, driven by a strong capital position and strategic divestments, although near-term revenue growth may be impacted by subdued loan demand and elevated costs.

  • Abbott Laboratories Growth: Abbott has shown strong performance in the medical products sector, with a promising pipeline and growth in its Medical Devices and Nutrition segments, despite facing challenges in diagnostics and macroeconomic pressures.

  • Shell's Financial Resilience: Shell's shares have outperformed the oil and gas sector, supported by strong LNG performance and disciplined capital management, though rising operating costs and revenue declines are pressuring margins.

[object Object]
Preview
5.0
00:41 AMPRnewswire
Abbott Launches New Protein Shakes to Support Muscle Health
  • New Product Launch: Abbott introduces two new protein shakes, Ensure Max Protein 42g and Ensure Max Protein 2 in 1 Muscle Support, targeting the muscle health needs of individuals over 40, particularly addressing the potential 8% muscle mass loss per decade.
  • Scientific Formulation: The new shakes contain up to 38% more protein and 3 grams of HMB, designed to help older adults slow muscle loss and build muscle tissue, thereby enhancing overall health outcomes.
  • Exclusive Market Availability: These products are currently available exclusively at Walmart and Walmart.com, with plans for expanded distribution to major retailers by April 2026, showcasing Abbott's strategic market positioning and responsiveness to consumer demand.
  • Health Impact: Research indicates a strong link between protein intake and blood sugar management, with data showing that users of Abbott's continuous glucose monitor had a 15% lower likelihood of elevated glucose levels on days they consumed protein shakes, further underscoring the importance of protein for overall wellness.
[object Object]
Preview
5.0
00:13 AMNewsfilter
Abbott Launches New Ensure Max Protein Shakes to Support Muscle Health
  • Product Innovation: Abbott has launched two new Ensure Max Protein shakes, namely Ensure Max Protein 42g for active adults providing 42 grams of complete protein, and Ensure Max Protein 2 in 1 Muscle Support for older adults offering 30 grams of protein and 1.5 grams of CaHMB, aimed at addressing diverse muscle health needs.
  • Market Positioning: These new shakes are specifically designed for individuals over 40, as research indicates that this age group can lose up to 8% of muscle mass per decade, with Abbott helping consumers combat muscle loss and enhance overall health through these products.
  • Nutritional Support: New data shows that consuming protein shakes can reduce the odds of elevated glucose levels by 15%, highlighting the importance of protein in maintaining muscle health and overall wellness, thereby reinforcing Abbott's leadership in the nutrition sector.
  • Sales Channels: Both new shakes are exclusively available at Walmart, with plans to expand to other major retailers by April 2026, demonstrating Abbott's keen insight into market demand and rapid responsiveness to consumer needs.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Abbott Laboratories (ABT) stock price today?

The current price of ABT is 125.4 USD — it has increased 0.09 % in the last trading day.

arrow icon

What is Abbott Laboratories (ABT)'s business?

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.

arrow icon

What is the price predicton of ABT Stock?

Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 147.13 USD with a low forecast of 136.00 USD and a high forecast of 162.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Abbott Laboratories (ABT)'s revenue for the last quarter?

Abbott Laboratories revenue for the last quarter amounts to 11.37B USD, increased 6.90 % YoY.

arrow icon

What is Abbott Laboratories (ABT)'s earnings per share (EPS) for the last quarter?

Abbott Laboratories. EPS for the last quarter amounts to 0.94 USD, decreased 0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Abbott Laboratories (ABT)'s fundamentals?

The market is revising Downward the revenue expectations for Abbott Laboratories (ABT) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -5.67%.
arrow icon

How many employees does Abbott Laboratories (ABT). have?

Abbott Laboratories (ABT) has 114000 emplpoyees as of December 05 2025.

arrow icon

What is Abbott Laboratories (ABT) market cap?

Today ABT has the market capitalization of 217.86B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free